About US
Contact us
-
Amarin for $20B? Novartis' MedCo deal drives fresh buyout rumors for Vascepa's makerDriven by a landmarkcardiovascular outcomes trial that could spell blockbuster sales for its fish-oil derivative, Vascepa, Amarin has been a darling for pharma M&A speculators. Now, after Novarti2019/11/25
-
Sanofi strategy exec Mansuri jumps ship ahead of new CEO's big revealNew Sanofi CEO Paul Hudson is days away from unveiling his plans for the French drugmaker, but the company's top strategy executive won't wait that long to leave. Muzammil Mansuri, Sanofi’s executive2019/11/22
-
FiercePharmaAsia—Novartis' Shanghai R&D revamp; BeiGene's Imbruvica rival; Shionogi's antibioticNovartis is refocusing its Shanghai R&D operation to drug development instead ofearly drug discovery. BeiGene nabbed the first FDA nod for a China-discovered cancer drug, a challenger to Johnson2019/11/22
-
SK Life Science plots 2020 launch for now-approved seizure drug XcopriSK Life Science has set out to transform itself into a commercial biopharmacompany, and with its seizure medXcopri now armed with an FDA approval,thedrugmakerisgearing up for its first-ever launch. F2019/11/21
-
BMS investors bet big on 3 newly acquired Celgene drugs for cancer and MSLate last year, Bristol-Myers Squibb made a last-minute revision of its offer to buy Celgene: Instead of paying $57 per share in cash and a one-to-one share trade, BMS offered $50, plus one BMS share2019/11/21
-
Antitrust reviews delay Roche's Spark deal further, but where are investors?As expected, Roche and Spark Therapeutics have once again delayed their tender offer for the $4.3 billion acquisition. “[T]o provide additional time for the U.S. Federal Trade Commission (FTC) and th2019/11/20
-
AbbVie's new launches Skyrizi, Rinvoq aren't getting enough credit: analystAbbVie has held high hopes for newcomers Skyrizi and Rinvoq as post-Allergan merger business drivers with the ongoing decline of Humira. But with prescription figures and market access tracking way a2019/11/20
-
Bankrupt Insys offers to turn out its almost empty pockets for plaintiffsAmidst a "fire sale" restructuring of bankrupt Insys, the former maker of notorious fentanyl spray Subsys, opioid plaintiffs are still hoping to pick some meat off the drugmaker's bones. And now, Ins2019/11/19
-
Amgen juices up sales outlook amid high hopes for Celgene castoff OtezlaWhen Amgen said it would hand over $13.4 billion forCelgene’s hit psoriasis drug Otezla in August,analysts agreed it had overpaid by $2 billion. But they also predicted Amgen’s experience turning imm2019/11/19
-
J&J now has to fight thousands more Risperdal claims, thanks to Pennsylvania's high courtJohnson & Johnson has been battlinglegal issues on several fronts—ranging from opioids to talc to medical devices—and Wednesday, its fight got a little tougher. Pennsylvania’s Supreme Courtruledt2019/11/18